WASHINGTON — The budget deal announced in the Senate on Wednesday contained a provision surprising to drug companies and Medicare beneficiaries alike: a sooner-than-expected change to the program’s “donut hole” coverage gap.
The provision included in the budget plan would mean a sizable hit to the pharmaceutical industry. It would move from 2020 to 2019 a requirement that drug makers pick up a larger portion of costs for their medicines for Part D beneficiaries who reach the so-called “donut hole” — a gap in Medicare coverage where beneficiaries often have to pay eye-watering drug prices out of pocket up to a certain dollar amount.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
